Atrophic rhinitis vaccine approved in S Korea
A Taiwan-developed vaccine for progressive atrophic
rhinitis in pigs has been approved for sale by the South Korean, and the
pharmaceutical company that helped market the vaccine said it is also awaiting
approval from several other countries.
The vaccine, AR recombinant subunit PMT vaccine, was developed by a team
led by Chien Maw-sheng, a professor at the Graduate Institute of Veterinary
Pathology at National Chung Hsing University.
AR is an acronym for atrophic rhinitis
, while PMT is pasteurella multocida toxin.
press conference in Taipei, Chien said the vaccine, made by genetically
reassembling the surface proteins of the atrophic rhinitis virus, can stimulate
the pig's immune system to fight off infection.
Chien said the vaccine
is better than conventional counterparts in terms of easier production process,
higher safety and lower cost.
In the coming two years, the
pharmaceutical company hopes to help the vaccine enter the markets of China,
Thailand, Vietnam, the Philippines, Japan, the United States and Mexico.
Joey S.C. Yu, general manager of the Animal Health department of Bayer
HealthCare, Taiwan, said the vaccine is the first Taiwan-made animal vaccine
approved to enter a foreign market.
â€¢ Bayer Health Care
to the free Pig Progress newsletter
To comment, login here
Or register to be able to comment.